title: Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.
abstract: Autoimmune uveitis (AU), an inflammatory non-infectious process of the vascular layer of the eye, can lead to visual impairment and, in the absence of a timely diagnosis and suitable therapy, can even result in total blindness. The majority of AU cases are idiopathic, whereas fewer than 20 % are associated with systemic diseases. The clinical severity of AU depends on whether the anterior, intermediate, or posterior part of the uvea is involved and may range from almost asymptomatic to rapidly sight-threatening forms. Race, genetic background, and environmental factors can also influence the clinical picture. The pathogenetic mechanism of AU is still poorly defined, given its remarkable heterogeneity and the many discrepancies between experimental and human uveitis. Even so, the onset of AU is thought to be related to an aberrant T cell-mediated immune response, triggered by inflammation and directed against retinal or cross-reactive antigens. B cells may also play a role in uveal antigen presentation and in the subsequent activation of T cells. The management of AU remains a challenge for clinicians, especially because of the paucity of randomized clinical trials that have systematically evaluated the effectiveness of different drugs. In addition to topical treatment, several different therapeutic options are available, although a standardized regimen is thus far lacking. Current guidelines recommend corticosteroids as the first-line therapy for patients with active AU. Immunosuppressive drugs may be subsequently required to treat steroid-resistant AU and for steroid-sparing purposes. The recent introduction of biological agents, such as those targeting tumor necrosis factor-α, is expected to remarkably increase the percentages of responders and to prevent irreversible sight impairment. This paper reviews the clinical features of AU and its crucial pathogenetic targets in relation to the current therapeutic perspectives. Also, the largest clinical trials conducted in the last 12 years for the treatment of AU are summarized and critically discussed.
authors.affiliation: Internal Medicine Unit, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, 70124, Bari, Italy. marcella.prete@uniba.it.
authors.forename: Marcella
authors.initials: M
authors.lastname: Prete
authors.affiliation: Department of Otorhinolaryngology and Ophthalmology, University of Bari Medical School, Bari, Italy.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Dammacco
authors.affiliation: Internal Medicine Unit, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, 70124, Bari, Italy.
authors.forename: Maria Celeste
authors.initials: MC
authors.lastname: Fatone
authors.affiliation: Internal Medicine Unit, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Piazza G. Cesare 11, 70124, Bari, Italy.
authors.forename: Vito
authors.initials: V
authors.lastname: Racanelli
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000503:physiopathology* / Q000628:therapy*; D001402:B-Lymphocytes / Q000276:immunology; D001691:Biological Therapy / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014605:Uveitis / Q000503:physiopathology* / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D001324:Autoantigens; D007166:Immunosuppressive Agents
keywords: Autoimmune uveitis; Behçet’s disease; CD4(+) T cells; Immunosuppressive drugs; Spondyloarthropathies; Toll-like receptors
references.citation: Methods Mol Biol. 2012;900:443-69
references.pmid: 22933083
references.citation: Ocul Immunol Inflamm. 2006 Aug;14(4):225-31
references.pmid: 16911984
references.citation: Inflamm Allergy Drug Targets. 2013 Feb;12(1):38-45
references.pmid: 23441991
references.citation: J Ophthalmic Inflamm Infect. 2014 Jul 24;4:17
references.pmid: 25097673
references.citation: Invest Ophthalmol Vis Sci. 2012 Jul 27;53(8):4969-74
references.pmid: 22714898
references.citation: J Ophthalmic Inflamm Infect. 2013 Mar 25;3(1):43
references.pmid: 23522744
references.citation: Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2056-63
references.pmid: 15914623
references.citation: Exp Eye Res. 2006 Mar;82(3):389-94
references.pmid: 16143328
references.citation: Ocul Immunol Inflamm. 2014 Apr 16;:null
references.pmid: 24738997
references.citation: Int J Rheum Dis. 2013 Oct;16(5):568-77
references.pmid: 24164845
references.citation: Br J Ophthalmol. 2012 Jun;96(6):857-61
references.pmid: 22408231
references.citation: Ocul Immunol Inflamm. 2014 Feb;22(1):56-63
references.pmid: 24410427
references.citation: Br J Ophthalmol. 2011 Feb;95(2):209-13
references.pmid: 20584711
references.citation: Immunology. 1996 Jul;88(3):456-62
references.pmid: 8774365
references.citation: Am J Ophthalmol. 2005 Sep;140(3):509-16
references.pmid: 16196117
references.citation: Arthritis Rheum. 2005 Mar;52(3):826-32
references.pmid: 15751057
references.citation: Clin Exp Ophthalmol. 2009 Aug;37(6):595-601
references.pmid: 19702710
references.citation: Mol Vis. 2012;18:1865-72
references.pmid: 22876110
references.citation: Ophthalmology. 2012 Aug;119(8):1575-81
references.pmid: 22525047
references.citation: Semin Ophthalmol. 2011 Jul-Sep;26(4-5):312-5
references.pmid: 21958180
references.citation: Am J Ophthalmol. 2014 Mar;157(3):526-31
references.pmid: 24211361
references.citation: PLoS One. 2012;7(1):e29742
references.pmid: 22238646
references.citation: Am J Ophthalmol. 1987 Feb 15;103(2):234-5
references.pmid: 3812627
references.citation: Conn Med. 2012 Oct;76(9):533-44
references.pmid: 23155672
references.citation: Int Immunol. 2008 Feb;20(2):209-14
references.pmid: 18156624
references.citation: Mod Rheumatol. 2008;18(4):354-8
references.pmid: 18427720
references.citation: Invest Ophthalmol Vis Sci. 2010 Jan;51(1):383-9
references.pmid: 19696173
references.citation: Ocul Immunol Inflamm. 2013 Dec;21(6):434-9
references.pmid: 23957503
references.citation: Curr Allergy Asthma Rep. 2014 Jan;14(1):409
references.pmid: 24338488
references.citation: Ophthalmology. 2010 Feb;117(2):356-65
references.pmid: 19969366
references.citation: Arch Ophthalmol. 2012 May;130(5):592-8
references.pmid: 22652845
references.citation: Rheumatology (Oxford). 2011 Aug;50(8):1390-4
references.pmid: 21378109
references.citation: J Clin Invest. 2010 Sep;120(9):3073-83
references.pmid: 20811163
references.citation: Ophthalmic Epidemiol. 2008 Sep-Oct;15(5):285-93
references.pmid: 18850464
references.citation: Ophthalmology. 2014 Jan;121(1):358-64
references.pmid: 24011995
references.citation: BMC Ophthalmol. 2013 Apr 24;13:18
references.pmid: 23617902
references.citation: J Clin Rheumatol. 2014 Apr;20(3):141-5
references.pmid: 24662555
references.citation: Ann Rheum Dis. 2008 Jul;67(7):955-9
references.pmid: 17962239
references.citation: Invest Ophthalmol Vis Sci. 2001 Jan;42(1):170-6
references.pmid: 11133863
references.citation: Acta Ophthalmol. 2009 Jun;87(4):424-8
references.pmid: 18652578
references.citation: Best Pract Res Clin Rheumatol. 2008 Oct;22(5):793-809
references.pmid: 19028364
references.citation: Ann Rheum Dis. 1976 Aug;35(4):354-6
references.pmid: 970993
references.citation: J Ophthalmic Vis Res. 2011 Oct;6(4):284-308
references.pmid: 22454751
references.citation: Ocul Immunol Inflamm. 2010 Apr;18(2):91-6
references.pmid: 20370333
references.citation: J Ophthalmic Inflamm Infect. 2013 May 31;3(1):48
references.pmid: 23724805
references.citation: Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2465-71
references.pmid: 15980237
references.citation: Mol Vis. 2011;17:2970-7
references.pmid: 22128242
references.citation: Retina. 2010 Feb;30(2):310-6
references.pmid: 20175273
references.citation: Ophthalmology. 2013 Jan;120(1):186-92
references.pmid: 23062650
references.citation: Eye (Lond). 2012 Jan;26(1):17-28
references.pmid: 21960067
references.citation: Br J Ophthalmol. 2006 Jan;90(1):103-8
references.pmid: 16361678
references.citation: J Exp Med. 2006 Apr 17;203(4):851-6
references.pmid: 16585264
references.citation: Curr Eye Res. 2005 Nov;30(11):943-8
references.pmid: 16282128
references.citation: Clin Immunol Immunopathol. 1993 May;67(2):143-50
references.pmid: 8100190
references.citation: Expert Opin Emerg Drugs. 2011 Jun;16(2):309-22
references.pmid: 21210752
references.citation: Ocul Immunol Inflamm. 2012 Aug;20(4):255-61
references.pmid: 22564107
references.citation: J Interferon Cytokine Res. 2011 Oct;31(10):733-44
references.pmid: 21787221
references.citation: Ocul Immunol Inflamm. 2010 Dec;18(6):424-31
references.pmid: 20735294
references.citation: Int J Rheum Dis. 2010 Aug;13(3):246-52
references.pmid: 20704622
references.citation: Ocul Immunol Inflamm. 2011 Dec;19(6):397-400
references.pmid: 22106906
references.citation: J Biol Chem. 2011 Mar 11;286(10):8472-80
references.pmid: 21216963
references.citation: Am J Pathol. 2007 Aug;171(2):580-8
references.pmid: 17600119
references.citation: Am J Ophthalmol. 2009 Feb;147(2):332-338.e1
references.pmid: 19166713
references.citation: Semin Ophthalmol. 2005 Jul-Sep;20(3):191-7
references.pmid: 16282154
references.citation: Case Rep Ophthalmol Med. 2011;2011:329857
references.pmid: 22611509
references.citation: Mol Immunol. 2010 Nov-Dec;48(1-3):231-9
references.pmid: 20843553
references.citation: Ophthalmology. 2014 Jan;121(1):365-76
references.pmid: 24169255
references.citation: Ophthalmology. 2004 May;111(5):960-5
references.pmid: 15121375
references.citation: J Autoimmun. 2009 May-Jun;32(3-4):178-88
references.pmid: 19324519
references.citation: Autoimmun Rev. 2014 Apr-May;13(4-5):591-4
references.pmid: 24424168
references.citation: Curr Opin Ophthalmol. 2013 Nov;24(6):589-97
references.pmid: 24100371
references.citation: Ophthalmic Res. 2007;39(3):184-6
references.pmid: 17534119
references.citation: Autoimmun Rev. 2011 Feb;10(4):205-9
references.pmid: 20959149
references.citation: Ocul Immunol Inflamm. 2010 Jan;18(1):2-4
references.pmid: 20128640
references.citation: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references.pmid: 7249508
references.citation: Dev Ophthalmol. 2012;51:134-61
references.pmid: 22517211
references.citation: Mol Vis. 2011;17:3486-93
references.pmid: 22219644
references.citation: Ophthalmology. 2004 Apr;111(4):802-9
references.pmid: 15051216
references.citation: Am J Ophthalmol. 2009 Oct;148(4):500-509.e2
references.pmid: 19570522
references.citation: Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3475-82
references.pmid: 18421089
references.citation: Autoimmun Rev. 2010 Mar;9(5):A325-9
references.pmid: 20026258
references.citation: Br J Ophthalmol. 2007 Jan;91(1):105-10
references.pmid: 16943228
references.citation: Inflamm Bowel Dis. 2010 Aug;16(8):1393-6
references.pmid: 19998457
references.citation: Discov Med. 2014 Mar;17(93):155-62
references.pmid: 24641958
references.citation: Autoimmun Rev. 2014 Aug;13(8):840-9
references.pmid: 24704868
references.citation: Ophthalmology. 2010 Mar;117(3):576-84
references.pmid: 20031223
references.citation: J Ophthalmic Vis Res. 2011 Oct;6(4):233-40
references.pmid: 22454745
references.citation: Br J Ophthalmol. 2013 Feb;97(2):134-8
references.pmid: 23212204
references.citation: Arthritis Care Res (Hoboken). 2011 Apr;63(4):612-8
references.pmid: 21452272
references.citation: Mol Vis. 2011 Jan 18;17:170-6
references.pmid: 21264236
references.citation: Autoimmun Rev. 2014 Apr-May;13(4-5):550-5
references.pmid: 24440284
references.citation: Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1871-8
references.pmid: 15161852
references.citation: Ophthalmology. 2001 Jun;108(6):1134-9
references.pmid: 11382642
references.citation: Eye (Lond). 2009 May;23(5):1192-8
references.pmid: 18551142
references.citation: Am J Ophthalmol. 2010 Oct;150(4):534-542.e2
references.pmid: 20643395
references.citation: Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2547-54
references.pmid: 16723469
references.citation: Am J Ophthalmol. 2007 May;143(5):840-846
references.pmid: 17362866
references.citation: Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
references.pmid: 15019324
references.citation: Am J Ophthalmol. 2010 Mar;149(3):423-32.e1-2
references.pmid: 20042178
references.citation: J Neurosci Res. 1997 Aug 1;49(3):268-80
references.pmid: 9260738
references.citation: Ophthalmology. 2009 Nov;116(11):2188-98.e1
references.pmid: 19748676
references.citation: Expert Opin Drug Saf. 2015 Jan;14(1):111-26
references.pmid: 25323655
references.citation: Am J Ophthalmol. 1982 Aug;94(2):147-58
references.pmid: 6956239
references.citation: Orphanet J Rare Dis. 2012 Aug 29;7:57
references.pmid: 22932001